Brigatinib

Brigatinib, an ARIAD-developed medicine

About Brigatinib

Discovered by ARIAD Pharmaceuticals, brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations.